Payment overview · 2025
General Payments
$1,058.37
46 reported records · 14 companies
Healthcare provider profile · identity verified
Gary M Hollander, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WALLED LAKE, MI · NPI 1902896749
Verified facts
What the public records show
CMS Open Payments records show Gary M Hollander, DO received $1,058.37 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.73 | 22.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.32 | 12.8% | 7 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $134.71 | 12.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.77 | 9.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.76 | 6.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.06 | 5.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.08 | 4.7% | 2 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.79 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.33 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.47 | 4.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.21 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.94 | 3.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.20 | 2.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,058.37 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $122.21 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111.71 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.57 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.42 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.42 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.01 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.08 | 2 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $49.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.33 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.81 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 167 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
146 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 131 |
| Losartan Potassium | Losartan Potassium | 420 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 91 |
| Jardiance | Empagliflozin | 256 | 56 |
| Lisinopril | Lisinopril | 252 | 64 |
| Prednisone | Prednisone | 243 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 56 |
| Omeprazole | Omeprazole | 192 | 47 |
| Eliquis | Apixaban | 167 | 47 |
| Furosemide | Furosemide | 151 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 41 |
| Gabapentin | Gabapentin | 150 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 146 | 41 |
| Simvastatin | Simvastatin | 145 | 33 |
| Alprazolam | Alprazolam | 136 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 41 |
| Metformin Hcl | Metformin Hcl | 128 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 39 |
| Montelukast Sodium | Montelukast Sodium | 126 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 27 |
| Famotidine | Famotidine | 121 | 38 |
| Azithromycin | Azithromycin | 116 | 84 |
| Ipratropium Bromide | Ipratropium Bromide | 113 | 71 |
| Carvedilol | Carvedilol | 109 | 33 |
| Trazodone Hcl | Trazodone Hcl | 109 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 33 |
| Donepezil Hcl | Donepezil Hcl | 99 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 28 |
| Sertraline Hcl | Sertraline Hcl | 95 | 18 |
| Ozempic | Semaglutide | 89 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 28 |
| Buspirone Hcl | Buspirone Hcl | 82 | 25 |
| Allopurinol | Allopurinol | 79 | 24 |
| Entresto | Sacubitril/Valsartan | 72 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 30 |
| Farxiga | Dapagliflozin Propanediol | 69 | 26 |
| Methocarbamol | Methocarbamol | 68 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 19 |
| Meloxicam | Meloxicam | 67 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 39 |
| Trulicity | Dulaglutide | 60 | 20 |
| Bupropion Xl | Bupropion Hcl | 59 | 15 |
| Cefdinir | Cefdinir | 59 | 41 |
| Mirtazapine | Mirtazapine | 59 | 13 |
| Valsartan | Valsartan | 58 | 21 |
| Warfarin Sodium | Warfarin Sodium | 58 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 57 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 13 |
| Potassium Chloride | Potassium Chloride | 52 | 13 |
| Celecoxib | Celecoxib | 49 | 20 |
| Olanzapine | Olanzapine | 49 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 34 |
| Atenolol | Atenolol | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Mupirocin | Mupirocin | 46 | 40 |
| Spironolactone | Spironolactone | 45 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 23 |
| Mounjaro | Tirzepatide | 44 | 13 |
| Tramadol Hcl | Tramadol Hcl | 43 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Finasteride | Finasteride | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Baclofen | Baclofen | 40 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 26 |
| Fluconazole | Fluconazole | 36 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 24 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Irbesartan | Irbesartan | 31 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 15 |
| Temazepam | Temazepam | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Clotrimazole | Clotrimazole | 13 | 11 |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Vimpat | Lacosamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,058.37 · 46 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, KISUNLA, KRYSTEXXA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REBYOTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error